9th Lobby

Ninth District Headquarters Office - Hawthorne, NY

Dan Doyle Portrait (002)

2023 Ninth District President

Dr. Daniel Doyle

Managing your reviews

Protect your practice’s reputation

Manage online reviews and stay HIPPA-compliant with new toolkit.

Access here
ADA Podcast Hero Image

Find your path in the ADA Member App

Get career recommendations based on your interests with the app’s career path quiz.

Take the Quiz

Welcome to the Ninth District Dental Association

The Ninth District Dental Society was formed in 1909 and renamed to the Ninth District Dental Association in 2002. We have a membership of over 1500 dentists in 5 counties: Westchester, Rockland, Dutchess, Orange and Putnam.

In its quest to serve both the public and the profession, the Ninth District embodies the highest ideals.

The mission of the 9th District Dental Association is to serve and support its members and the public by improving the oral health of our community through Advocacy, Continuing Education and Camaraderie.

New Ninth District Lgo

New Dentist

Ice Cream Social

Wednesday, September 27th


We will have the Ice Cream Emergency truck!


FREE event with wonderful gourmet ice cream and toppings! Come mingle and meet other 9th District New Dentists and visit your 9th Headquarters!

Make friends and business colleagues!

Please spread the word to other new dentists.


Bank of America Practice Solutions
Kettenbach LP
MLMIC Insurance Company

To Register please call HQ 914-747-1199.

Latest News Around the Tripartite

Around the Ninth District

Webinar: "Update on Medication-Related Osteonecrosis of the Jaw"

"Update on Medication-Related Osteonecrosis of the Jaw"


Instructor:  Ken Fleisher, D.D.S., F.A.C.S., Clinical Professor

Bone health and maintenance of bone integrity are important concerns during comprehensive cancer care and management of osteoporosis.  Bisphosphonates and denosumab are antiresorptive medications widely used for the prevention and treatment of osteoporosis and skeletal complications associated with metastatic cancer and multiple myeloma.  Medication-related osteonecrosis of the jaw (MRONJ), related to antiresorptive therapy, is a condition that has created numerous dilemmas in patient management and may have a broad health impact.  Minimizing the risk of MRONJ is critical, not only to prevent MRONJ, but also to maximize the benefit of antiresorptive therapy. This case-based presentation will review evidence-based data that has led to paradigm shifts for pathogenesis and innovative strategies for risk assessment, prevention and management of MRONJ.